XTX Topco Ltd Invests $108,000 in RAPT Therapeutics, Inc. (NASDAQ:RAPT)

XTX Topco Ltd purchased a new position in RAPT Therapeutics, Inc. (NASDAQ:RAPT) during the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor purchased 35,480 shares of the company’s stock, valued at approximately $108,000. XTX Topco Ltd owned about 0.10% of RAPT Therapeutics at the end of the most recent quarter.

Several other institutional investors also recently added to or reduced their stakes in the stock. China Universal Asset Management Co. Ltd. grew its stake in RAPT Therapeutics by 65.8% in the 1st quarter. China Universal Asset Management Co. Ltd. now owns 6,602 shares of the company’s stock worth $59,000 after acquiring an additional 2,621 shares in the last quarter. Hennion & Walsh Asset Management Inc. grew its stake in RAPT Therapeutics by 8.6% in the second quarter. Hennion & Walsh Asset Management Inc. now owns 48,525 shares of the company’s stock worth $148,000 after purchasing an additional 3,824 shares in the last quarter. Acadian Asset Management LLC purchased a new position in RAPT Therapeutics during the 1st quarter worth $97,000. EntryPoint Capital LLC bought a new stake in RAPT Therapeutics during the 1st quarter valued at $161,000. Finally, Artia Global Partners LP purchased a new stake in shares of RAPT Therapeutics in the 4th quarter worth $488,000. Hedge funds and other institutional investors own 99.09% of the company’s stock.

RAPT Therapeutics Price Performance

Shares of RAPT stock opened at $1.85 on Wednesday. The company has a market cap of $64.57 million, a P/E ratio of -0.60 and a beta of 0.33. The stock’s 50-day moving average is $2.28 and its 200 day moving average is $4.41. RAPT Therapeutics, Inc. has a 1-year low of $1.73 and a 1-year high of $27.35.

RAPT Therapeutics (NASDAQ:RAPT) last posted its quarterly earnings data on Thursday, August 8th. The company reported ($0.71) EPS for the quarter, topping the consensus estimate of ($0.74) by $0.03. On average, analysts anticipate that RAPT Therapeutics, Inc. will post -2.73 EPS for the current year.

Wall Street Analyst Weigh In

Several brokerages have recently commented on RAPT. HC Wainwright restated a “neutral” rating on shares of RAPT Therapeutics in a research note on Tuesday, August 20th. UBS Group reduced their price target on shares of RAPT Therapeutics from $10.00 to $2.00 and set a “neutral” rating for the company in a report on Monday, September 9th. Nine investment analysts have rated the stock with a hold rating and one has assigned a buy rating to the company’s stock. According to MarketBeat.com, the company has an average rating of “Hold” and an average price target of $18.17.

RAPT Therapeutics Company Profile

RAPT Therapeutics, Inc, a clinical-stage immunology-based biopharmaceutical company, focuses on discovery, development, and commercialization of oral small molecule therapies for patients with unmet needs in oncology and inflammatory diseases in the United States. The company's lead inflammation drug candidate is zelnecirnon (RPT193), a C-C motif chemokine receptor 4 (CCR4) antagonist that selectively inhibit the migration of type 2 T helper cells into inflamed tissues.